Abdominal discomfort abdominal pain

Document Sample
Abdominal discomfort abdominal pain Powered By Docstoc
					                         [Indian Journal of Clinical Practice (2002): 12 (12), 45-48,60]

       Non-ulcer Dyspepsia: A Clinical Trial Evaluating Efficacy and Safety
                       with a Natural Antacid - Himcocid
                                                  Tripathi, K.,
                                    Professor & Head,Department of Medicine,
             Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.

                           [Corresponding author: Dr. Kala Suhas Kulkarni, M.D.
             Medical Advisor, R&D Center, The Himalaya Drug Company,Makali, Bangalore, India]

Dyspepsia encompasses a variety of upper abdominal symptoms i.e., pain and discomfort, bloating,
fullness, nausea, anorexia, heartburn and belching. Herbal drugs have been known to provide a
new therapeutic approach to treat non-ulcer dyspepsia. Fifty patients with symptoms of non-ulcer
dyspepsia were treated with an herbal preparation Himcocid for a period of 6 weeks. The dosage of
Himcocid was 2 teaspoonsful, twice a day. After 6 weeks, there was 96.5% relief from epigastric
discomfort (p<0.0001), total relief from heartburn (p<0.0001) 95.32% relief in nausea relieved and
98.48% (p<0.001) relief in vomiting. There was 100% relief from belching, flatulence and fullness
in the stomach (p<0.001). Abdominal distension was relieved in 98.25% (p<0.0001). There was no
untoward side effect such as rebound gastritis in any of the patients. The study shows promising
treatment of non-ulcer dyspepsia with Himcocid.

The term “dyspepsia,” derived from the Greek words dys (bad) and pepsis (digestion), refers to
symptoms thought to originate in the upper gastrointestinal tract1,2. Dyspepsia is often used to refer
to upper abdominal pain or discomfort but may also encompass symptoms of early satiety,
postprandial abdominal bloating or distension, nausea and vomiting3. Although only 20-25% of
persons with dyspepsia seek medical care, the problem is responsible for 2 to 5 percent of visits to
the physicians4. Non-ulcer dyspepsia results in substantial health care costs, both in direct costs of
visits to doctors, expensive tests and medications, and absenteeism from work and diminished
productivity at the workplace5.

Functional or idiopathic dyspepsia commonly occurs as a chronic digestive disorder affecting 20-
40% of the general population6. This condition is characterized by a recurring variable cluster of
upper abdominal symptoms associated with food intake for which no evidence of organic disease
can be found. Like other functional disorders of the gastrointestinal system such as irritable bowel
syndrome and gastro-oesophageal reflux, the understanding of the pathophysiological mechanisms
underlying this condition remains elusive. Motor, neurohumoral and sensory abnormalities in both
the stomach7 and small bowel have been demonstrated in some patients with functional dyspepsia,
but attempts to classify patients into dyspepsia subgroups based on predominating symptoms linked
to such disturbances (dysmotility-like, ulcer-like, reflux-like dyspepsia) do not seem helpful. Many
patients have more than one symptom in non-ulcer dyspepsia. Moreover, about one third of patients
with functional dyspepsia also have symptoms associated with irritable bowel syndrome8. This may
explain why the response to drug treatment of dyspepsia based on a symptom-oriented classification
may be too narrow an approach.

In the investigators’ meeting in Rome in 1991, it was decided that the criteria for diagnosing non-
ulcer dyspepsia are chronic or recurrent upper abdominal pain or discomfort for a period of at least 1
month, with symptoms present more than 25 percent of the time. There should also be an absence of
clinical, biochemical, endoscopic and ultrasonographic evidence of organic disease that would
account for the symptoms9. Despite these criteria, there is still some overlap between the symptoms
of dyspepsia and those of irritable bowel syndrome.

The Rome group also suggested that it might be useful to subcategorize non-ulcer dyspepsia into
ulcer-like, reflux-like, dysmotility-like, and nonspecific dyspepsia. Reflux-like dyspepsia is
characterized by heartburn, regurgitation, or both, with dyspeptic symptoms and no endoscopic
evidence of oesophagitis. Epigastric pain is the predominant symptom of ulcer-like dyspepsia.
Symptoms of nausea, vomiting, early satiety, and abdominal bloating or distension characterize
dysmotility like dyspepsia. The usefulness of this sub-classification based on symptoms has been
questioned, since studies have reported a marked overlap among the subtypes. Also, the symptom-
based sub-classification provides little information about the underlying pathophysiologic
abnormality, such as gastroduodenal ulcer or gastroparesis10. In recent times many herbs have been
used to treat dyspeptic symptoms and also for the treatment of peptic ulcers. Many advance research
laboratories have been established to find herbal remedies for various disorders, which are devoid
of adverse side effects. Thus, we decided to study a herbal preparation known as Himcocid.
Himcocid contains herb such as Varatika, which is helpful in the treatment of symptoms of non-
ulcer dyspepsia. Yasthimadhu is well known for it’s anti-ulcer properties. Dugdhapashna and
Moutika Sukti, the other ingredients of Himcocid, are helpful in reducing the symptoms of non-
ulcer dyspepsia.

In a clinical study, after 45 days of Himcocid therapy, the result showed that all the symptoms of
non-ulcer dyspepsia were reduced which was evident when the scaling of the symptoms was
considered. Initially the symptom score of epigastric discomfort, heartburn, nausea, vomiting,
belching, flatulence, fullness in stomach and abdominal distension ranged from 0.38 ± 0.73 to 2.24
± 0.84. At the end of the study all the symptoms were relieved and the symptom score was 011. In
another study, there was reduction in all the symptoms from 2 weeks onwards. It was observed that
there was excellent to good response in 86 – 87% of the patients after treatment. At the end of the
study, the investigators rated efficacy and tolerance of treatment as excellent to good in 90% of the
patients. Endoscopy was repeated in a majority of cases, and the results showed a significant
improvement in healing12.

The study was planned in 50 patients with non-ulcer dyspepsia with symptoms of epigastric
discomfort, heartburn, nausea, vomiting, belching, flatulence, fullness in stomach and abdominal
distension. Pain attributed to angina or gallbladder stones was ruled out after history-taking of the
patients. Patients who suffered from thyroid and parathyroid disorders, hypertension, gastric
carcinoma and diagnosed peptic or duodenal ulcer were also excluded. Of 50 patients there were 31
males and 19 females, aged between 18-60 years. All the patients had epigastric discomfort, 39
patients had heartburn, 18 patients had nausea, 3 patients had vomiting, 12 patients had belching, 13
patients had flatulence, 26 patients suffered from fullness in stomach and 16 patients had abdominal
distension. The patients were dispensed Himcocid suspension and advised to take the medicine at a
dose of 2 teaspoonsful twice a day for 6 weeks. They were evaluated every 2 weeks for
improvement in the dyspeptic symptoms and to observe for any adverse events.

All the 50 patients completed the 6 weeks study period. It was found that relief was observed from
the 2nd week onwards and at the end of 6 weeks they were very few negligible symptoms of
dyspepsia. The assessment was done by grading the symptoms as 4 – very severe (unbearable), 3 -
severe, 2 - moderate, 1 - mild and 0- no symptom.

At the beginning of the study all 50 patients       Table 1: Patients showing clinical response of Himcocid
had epigastric discomfort, 39 patients had                          in Non-ulcer dyspepsia
heartburn, nausea was present in 18 patients, Symptoms No. of               After 2     After 4     After 6
                                                                patients     weeks       weeks       weeks
vomiting in 3, belching in 12, flatulence in
                                                   Epigastric                  17          32          48
13, fullness in stomach in 36 and abdominal discomfort             50
                                                                             (34%)       (64%)       (96%)
distension was present in 16 patients. After 2                                 13          29          39
weeks of therapy, epigastric discomfort was Heartburn              39
                                                                           (33.33%) (74.35%)        (100%)
relieved in 17 patients, after 4 weeks, 32 Nausea                  18
                                                                               6           12          17
patients and at the end of the therapy, 48                                 (33.33%) (66.66%) (94.44%)

patients were completely relieved of the Vomiting                              1            2           3
                                                                           (33.33%) (66.66%)        (100%)
symptoms. Heartburn was relieved in 13
                                                                               4                       12
patients after 2 weeks in 29 patients after 6 Belching             12
                                                                                        9 (75%)
weeks and in 39 patients after 6 weeks. Six                                    5           10          13
                                                   Flatulence      13
patients were relieved from nausea after 2                                 (38.46%) (76.92%)        (100%)
weeks, 12 patients after 4 weeks and 17 Fullness in                26
                                                                               11          20
                                                                                                   26 (100%)
                                                   stomach                 (42.30%) (76.92%)
patients after 6 weeks. Vomiting was relieved
                                                   Abdominal                   6           11          15
in 1 patient after 2 weeks, in 2 patients after 4 discomfort       16
                                                                            (37.5%) (68.75%) (93.75%)
weeks and in 3 patients after 6 weeks.
Belching, flatulence and fullness of stomach was relieved in 4, 5 and 11 patients, respectively, after
2 weeks, 9, 10 and 20 patients after 4 weeks and total relief after 6 weeks. Abdominal distension
was relieved in 6 patients after 2 weeks, in 11 patients after 4 weeks and in 15 patients after 6 weeks
of Himcocid therapy (Table 1). No adverse reaction was observed in any of the patients.

A number of hypotheses have been proposed to explain the pathogenesis of non-ulcer dyspepsia.
The gastric acid hypothesis advocates that either hypersecretion of gastric acid or increased
sensitivity to it is responsible for dyspeptic symptoms. The motor-disorder hypothesis suggests that
motor disorders of the upper gastro-intestinal tract, such as gastro0esophageal reflux disease,
gastroparesis, small-bowel dysmotility, and biliary dyskinesia cause dyspeptic symptoms. The
hypothesis of augmented visceral perception suggests that dyspeptic symptoms are exaggerated
responses to physical stimuli such as pressure, distension and temperature. Finally, the food-
intolerance hypothesis proposes that certain foods may cause dyspeptic symptoms by triggering
secretory motor or allergic responses.
Despite the use of the term “non ulcer dyspepsia,” which suggests an idiopathic functional disorder,
a number of non-motility and motility disorders have been identified as potential causes. For years,
physicians have treated patients with pain like that associated with ulcer (epigastric pain that occurs
after meals and at night and that is relieved with antacids), but with no ulcer on examination13. In
some patients, subsequent endoscopy may reveal an ulcer, suggesting that the initial symptoms were
those of an “ulcer diathesis”14. In some patients with dyspeptic symptoms, the duodenal mucosa
may appear mottled, hyperemic, or irregular on endoscopy, with duodenitis noted on biopsy15. The
clinical significance of histologic duodenitis is doubtful, since it is often found in healthy adults and
since there is little improvement in the appearance of the mucosa with treatment, regardless of the
symptomatic response16.

Few cases of dyspepsia may represent various stages of Helicobacter pylori infection and may
subsequently progress to ulcer disease17. H. pylori infection has a prevalence of upto 1 percent per
year of age. The age-related prevalence may be higher in patients with non-ulcer dyspepsia, but this
finding has not been confirmed by all investigators18,19. Dyspeptic symptoms have been reported
after intentional self-infection with H. pylori20. Although some studies have demonstrated an
improvement in dyspeptic symptoms after the eradication of H. pylori, an equal number of studies
did not21,22.

Another potential cause of non-ulcer dyspepsia is reflux of bile into the stomach. However,
objective studies have shown that patients with dyspepsia who have not undergone prior surgery do
not have elevated bile acid concentrations in the stomach23. Medicines to treat this type of gastritis
are unavailable or ineffective.

When one cannot explain a patient’s intractable symptoms, there is often supposition that it could be
a manifestation of an underlying psychiatric disorder. Regardless of whether the cause is functional
or organic, patients with abdominal pain have higher scores for depression, anxiety, neuroticism,
and hypochondriasis than patients without abdominal pain. Exacerbations of non-ulcer dyspepsia are
often attributed to stressful events. One study suggests that patients with non-ulcer dyspepsia and
patients with other disorders have similar numbers of stressful events in their lives but that patients
with dyspepsia report greater stress.

In upto 60 percent of patients with dyspepsia, the diagnostic evaluation discloses no underlying
organic cause24. Such patients are labeled as having non-ulcer, or functional, dyspepsia. This
disorder is considered to be part of a continuum of functional gastrointestinal disorders that include
irritable bowel syndrome, functional heartburn, and non-cardic chest pain.

The pathophysiology of non-ulcer dyspepsia is poorly understood25,26. In more than half of affected
patients, inflation of an intragastric balloon will cause pain at volumes significantly lower than
those that cause pain in healthy subjects, suggesting the presence of increased visceral sensitivity.
Upto half of patients have delayed gastric emptying of solids or postprandial antral hypomotility.
Unfortunately, the demonstration of these abnormalities does not correlate with symptomatic
improvement after treatment with agents that promote motility, such as cisapride. As compared with
healthy subjects, patients with non-ulcer dyspepsia have higher scores for anxiety, neuroticism, and
depression on personality assessment, but it is unclear whether these traits merely reflect the fact
that these patients will seek health care27.

Extensive, and many a times inconsistent, data on the treatment of non-ulcer dyspepsia are present.
Treatment approaches that have been extensively prescribed included the use of antacids, the use of
H2receptor antagonists and antibiotics for the eradication of H. pylori. Several careful meta-analyses
have been performed, allowing some general statements about treatment for non-ulcer dyspepsia. In
clinical studies, higher doses of acid-suppressing agents had a positive effect on the symptoms, with
improvement reported in 35 to 80 percent of patients receiving the acid-suppressing agents, as
compared with 30 to 60 percent of those receiving placebo28,29. In two preliminary studies of
omeprazole, a proton-pump inhibitor for the treatment of non ulcer dyspepsia, only 50 percent of the
patients treated with omeprazole responded, as compared with 25 percent of those who received a

It is not advisable to perform extensive diagnostic tests such as esophago-gastroduodenoscopy,
biliary tract ultrasonography, or even abdominal computed tomography in all patients. Whether all
patients who present with dyspeptic symptoms should at least undergo initial endoscopy is
controversial. Empirical therapy is advisable in patients who do not have signs or symptoms of an
underlying organic disorder, such as gastric ulcer or cancer. This was the reason why we did not
subject the patients in the study to gastroendoscopy.

In this study, the epigastric discomfort that was present in all the patients disappeared after six
weeks of Himcocid therapy and only 3.5% had mild symptoms. Nausea, present in 36% at the
beginning, was present in only 4.68%. Vomiting, present in 6% before therapy, was present in
1.52% after therapy, which was mild occasionally. Heartburn, belching, flatulence and fullness of
stomach was absent in all the patients. Abdominal distension was seen in only 1.75% (Table 1).
These studies thus indicate that herbal preparations such as Himcocid can be a useful alternative
medicine in patients with dyspeptic symptoms.

A promising finding, which emerges from this study, was that Himcocid appears to improve
gastrointestinal sensitivity at the level of integration, which may involve the entire digestive tract.
The use of Himcocid could offer a broader therapeutic option in the treatment of non-ulcer

1.  Talley NJ, Phillips SF. Non-ulcer dyspepsia: Potential causes and pathophysiology. Annals of
    Internal Medicine 1988;108:865-879.

2.    Camilleri M. Non-ulcer dyspepsia: A look into the future. Mayo Clinic Proceedings

3.    Barbara L, Camilleri M, Corinaldesi R, et al. Definition and investigation of dyspepsia -
      consensus of an international ad hoc working party. Digestive Diseases and Sciences
4.    Brown C and Rees WDW. Dyspepsia in general practice. British Medical Journal

5.    Nyren O, Adami HO, Gustavsson S and Loof L. Excess sick-listing in non ulcer dyspepsia.
      Journal of Clinical Gastroenterology 1986;8:339-345.

6.    Jones R and Lydeard S. Prevalence of symptoms of dyspepsia in the community. Lancet

7.    Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying
      and abnormal gastrointestinal motility. Gastroenterology 1986;91:94-99 (Abstract).

8.    Talley NJ and Piper DW. The association between non-ulcer dyspepsia and other
      gastrointestinal disorders. Scandinavian Journal of Gastroenterology 1985;20:896-900

9.    Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyren O, Stanghellini V. Functional dyspepsia:
      a classification with guidelines of diagnosis and management. Gastroenterol Int 1991;4:145-

10.   Malagelada J-R. Functional dyspepsia—insights on mechanisms and management strategies.
      Gastroenterology Clinics of North America 1996;25:103-112.

11.   Upadhyaya, B.N., Upadhyaya and Khagen Basumathy. Clinical evaluation of Himcocid
      suspension in patients with non-ulcer dyspepsia. The Antiseptic 2001;98(11):409-411.

12.   Rangamani, K., Clinical Trial of Efcid in Patients of Acid Peptic Disease. The Antiseptic

13.   Spiro HM. Moynihan’s disease? The diagnosis of duodenal ulcer. New England Journal of
      Medicine 1974;291:567-569.

14.   Sircus W. Duodenitis: A clinical, endoscopic and histopathologic study. Quarterly Journal of
      Medicine 1985;56:593-600.

15.   Tytgat GN, Noach LA and Rauws EAJ. Is gastroduodenitis a cause of chronic dyspepsia?
      Scandinavian Journal of Gastroenterology Supplement 1991;182:33-39.

16.   Johnsen R, Bernersen B, Straume B, Forde OH, Bostad L and Burhol PG. Prevalences of
      endoscopic and histological findings in subjects with and without dyspepsia. British Medical
      Journal 1991;302:749-752.

17.   Tytgat GNJ. Current indications for Helicobacter pylori eradication therapy. Scandinavian
      Journal of Gastroenterology Supplement 1996;215:70-73.

18.   Armstrong D. Helicobacter pylori infection and dyspepsia. Scandinavian Journal of
      Gastroenterology Supplement 1996;215:38-47.

19.   Veldhuyzen van Zanten SJ, Sherman PM. Helicobacter pylori infection as a cause of gastritis,
      duodenal ulcer, gastric cancer and non ulcer dyspepsia: A systematic overview. Canadian
      Medical Association Journal 1994;150:177-185.
20.   Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfill Koch’s postulates
      for pyloric Campylobacter. Medical Journal of Australia 1985;142:436-439.

21.   O’Morain C, Buckley M. Helicobacter pylori and dyspepsia. Scandinavian Journal of
      Gastroenterology Supplement 1996;214:28-30.

22.   Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia.
      Gastroenterology 1994;106:1174-1183.

23.   Bost R, Hostein J, Valenti M, et al. Is there an abnormal fasting duodenogastric reflux in non
      ulcer dyspepsia? Digestive Diseases and Sciences 1990;35:193-199.

24.   Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical
      review: Evaluation of dyspepsia. Gastroenterology 1998;114:582-595.

25.   McQuaid K. Dyspepsia. In: Sleisenger and Fordtran’s gastrointestinal and liver disease:
      Pathophysiology/diagnosis/management 6th Edition, Feldman M, Sleisenger MH and
      Scharschmidt BF , (Eds.), W.B. Saunders, Philadelphia 1998;1:105-117.

26.   Fisher RS, Parkman HP. Management of nonulcer dyspepsia. New England Journal of
      Medicine 1998;339:1376-1381.

27.   Tally NJ, Boyce P, Jones M. Dyspepsia and health care seeking in a community: How
      important are psychological factors? Digestive Diseases and Sciences 1998;43:1016-1022.

28.   Dobrilla G, Comberlato M, Steele A and Vallaperta P. Drug treatment of functional
      dyspepsia: A meta-analysis of randomized controlled clinical trials. Journal of Clinical
      Gastroenterology 1989;11:169-177.

29.   Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, et al. Drug treatment of functional
      dyspepsia: A systematic analysis of trial methodology with recommendations for design of
      future trials. American Journal of Gastroenterology 1996;91:660-673.

30.   Carlsson R, Bolling E, Jerndal P, Junghard O, Lauritsen K and Glise H. Factors predicting
      response to omeprazole treatment in patients with functional dyspepsia. Gastroenterology
      1996;110(Suppl.):A76-A76 (Abstract).

31.   Meineche-Schmidt V, Krag E, Christensen E. Identification of omeprazole response in
      dyspepsia: data analysis of a Danish multicenter trial in general practice. Gastroenterology

Shared By:
Description: Abdominal discomfort abdominal pain